Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

eTRANSAFE: data science to empower translational safety assessment

Thirteen pharmaceutical companies have shared and integrated preclinical and clinical data for creating computational resources that enhance translational drug safety assessment.
By
  1. Ferran Sanz

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.

  2. François Pognan

    1. Novartis Pharma, Basel, Switzerland.

  3. Thomas Steger-Hartmann

    1. Bayer, Berlin, Germany.

  4. Carlos Díaz

    1. Synapse Research Management Partners, Madrid, Spain.

  5. Shoji Asakura

    1. Eisai, Tsukuba, Ibaraki, Japan.

  6. Alexander Amberg

    1. Preclinical Safety, Sanofi, Frankfurt am Main, Germany.

  7. Nathalie Bécourt-Lhote

    1. Non-Clinical Drug Safety, Translational Medicine, Servier, Suresnes, France.

  8. Niklas Blomberg

    1. ELIXIR, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

  9. Nicolas Bosc

    1. European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

  10. Katharine Briggs

    1. Lhasa Limited, Leeds, UK.

  11. Frank Bringezu

    1. Chemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, Germany.

  12. Claire Brulle-Wohlhueter

    1. Translational and Genomic Medicine Safety, Sanofi, 91380 Chilly-Mazarin, France.

  13. Søren Brunak

    1. Technical University of Denmark (DTU), Lyngby, Denmark; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Present address: Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.

  14. Ruud Bueters

    1. Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.

  15. Giulia Callegaro

    1. Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.

  16. Salvador Capella-Gutierrez

    1. Barcelona Supercomputing Center (BSC), Barcelona, Spain.

  17. Emilio Centeno

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.

  18. Javier Corvi

    1. Barcelona Supercomputing Center (BSC), Barcelona, Spain.

  19. Mark T. D. Cronin

    1. Liverpool John Moores University, Liverpool, UK.

  20. Philip Drew

    1. PDS Consultants, Leicester, UK.

  21. Guillemette Duchateau-Nguyen

    1. Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.

  22. Gerhard F. Ecker

    1. Universität Wien, Vienna, Austria.

  23. Sylvia Escher

    1. Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.

  24. Eloy Felix

    1. European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

  25. Miguel Ferreiro

    1. GMV, Tres Cantos, Madrid, Spain.

  26. Markus Frericks

    1. BASF, Ludwigshafen, Germany.

  27. Laura I. Furlong

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; MedBioinformatics Solutions, Barcelona, Spain.

  28. Robert Geiger

    1. BASF, Ludwigshafen, Germany.

  29. Catherine George

    1. Ipsen Innovation, Les Ulis, France.

  30. Melanie Grandits

    1. Universität Wien, Vienna, Austria.

  31. Dragomir Ivanov-Draganov

    1. Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.

  32. Jean Kilgour-Christie

    1. Novartis Pharma, Basel, Switzerland.

  33. Tevfik Kiziloren

    1. European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

  34. Jan A. Kors

    1. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.

  35. Naoki Koyama

    1. Eisai, Tsukuba, Ibaraki, Japan.

  36. Annika Kreuchwig

    1. Bayer, Berlin, Germany.

  37. Andrew R. Leach

    1. European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

  38. Miguel-Angel Mayer

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.

  39. Peter Monecke

    1. Preclinical Safety, Sanofi, Frankfurt am Main, Germany.

  40. Wolfgang Muster

    1. Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.

  41. Chihiro Miyamoto Nakazawa

    1. Eisai, Tsukuba, Ibaraki, Japan.

  42. Gavin Nicholson

    1. Optibrium Ltd., Cambridge Innovation Park, Cambridge, UK.

  43. Rowan Parry

    1. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.

  44. Manuel Pastor

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.

  45. Janet Piñero

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; MedBioinformatics Solutions, Barcelona, Spain.

  46. Nils Oberhauser

    1. Novartis Pharma, Basel, Switzerland.

  47. Juan Manuel Ramírez-Anguita

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.

  48. Adrián Rodrigo

    1. GMV, Tres Cantos, Madrid, Spain.

  49. Aljosa Smajic

    1. Universität Wien, Vienna, Austria.

  50. Markus Schaefer

    1. Preclinical Safety, Sanofi, Frankfurt am Main, Germany.

  51. Sebastian Schieferdecker

    1. Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.

  52. Inari Soininen

    1. Synapse Research Management Partners, Madrid, Spain.

  53. Emma Terricabras

    1. Hospital del Mar Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.

  54. Panuwat Trairatphisan

    1. AbbVie Germany, Ludwigshafen am Rhein, Germany.

  55. Sean C. Turner

    1. AbbVie Germany, Ludwigshafen am Rhein, Germany.

  56. Alfonso Valencia

    1. Barcelona Supercomputing Center (BSC), Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

  57. Bob van de Water

    1. Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.

  58. Johan L. van der Lei

    1. Synapse Research Management Partners, Madrid, Spain; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.

  59. Erik M. van Mulligen

    1. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.

  60. Esther Vock

    1. Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.

  61. David Wilkinson

    1. Lhasa Limited, Leeds, UK.

Access through your institution
Buy or subscribe

Drug research and development (R&D) is knowledge-intensive, and so can benefit from advances in data science and technologies, such as automated data curation, data integration and artificial intelligence. Data sharing beyond the boundaries of individual pharmaceutical companies offers particularly interesting opportunities for accelerating and improving aspects of the R&D process. However, balancing collaboration and confidentiality remains a complex challenge for the industry.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 605-606 (2023)

doi: https://doi.org/10.1038/d41573-023-00099-5

References

  1. Pognan, F. et al. The eTRANSAFE project on translational safety assessment through integrative knowledge management: achievements and perspectives. Pharmaceuticals (Basel). 14, 237 (2021).

    Article  PubMed  Google Scholar 

  2. Piñero, J. et al. Genomic and proteomic biomarker landscape in clinical trials. Comput. Struct. Biotechnol. J. 21, 2110–2118 (2023).

    Article  PubMed  Google Scholar 

  3. Callegaro, G. et al. The human hepatocyte TXG-MAPr: gene co-expression network modules to support mechanism-based risk assessment. Arch. Toxicol. 95, 3745–3775 (2021).

    Article  PubMed  Google Scholar 

  4. Pastor, M., Gómez-Tamayo, J. C. & Sanz, F. Flame: an open-source framework for model development, hosting, and usage in production environments. J. Cheminform. 13, 31 (2021).

    Article  PubMed  Google Scholar 

  5. Steger-Hartmann, T. et al. Perspectives of data science in preclinical safety assessment. Drug Discov. Today 28, 103642 (2023).

    Article  PubMed  Google Scholar 

  6. Clark, M. & Steger-Hartmann, T. A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans. Regul. Toxicol. Pharmacol. 96, 94–105 (2018).

    Article  PubMed  Google Scholar 

  7. Steger-Hartmann, T. et al. Introducing the concept of virtual control groups into preclinical toxicology testing. ALTEX 37, 343–349 (2020).

    PubMed  Google Scholar 

Download references

Competing Interests

Some authors are employed in the pharmaceutical industry or in small-and-medium sized enterprises, as indicated in their affiliations. The other authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links